Nanodose Therapeutics is a biopharmaceutical company focused on developing safe and effective treatments to tackle on chronic conditions,

​

Our portfolio of products and our proprietary formulation technology address significant unmet medical needs. Our portfolio consists of patent protected, late-stage, well-characterized molecules with clear regulatory paths to approval. We will utilize both the BLA approval pathway and maintain an open dialogue and communication with the FDA to reduce development costs, shorten approval timelines, and optimize the chances of approval. And upon each approval, the expectation that we will have 12 years of regulatory exclusivity. Our pipeline products will compete in large markets that have significant unmet medical needs. 

​

Our programs include:

​

• NT-101 (oSLO) is our lead asset and is a recombinant protein that could be the first product approved for chronic Traumatic Brain Injury. It could provide the efficacy and the safety necessary to make a remarkable impact on the quality of life for patients suffering from this devastating condition.  

​

• NT-201 (oSLO plus an undisclosed compound) which is under development for another chronic and devastating condition – Alzheimer’s Disease. Alzheimer's affects close to 7 million people in the U.S.

​​

• NT-202 (oSLO plus an undisclosed compound) is another product in development that also takes aim at another chronic neurological condition. Stroke is not only the 5th leading cause of death in the U.S., but costs the healthcare system in excess of $56 Billion each year.

​

• NT-203 (oSLO plus an undisclosed compound) is our next generation treatment for Chronic Traumatic Brain injury and combines oSLO with another undisclosed compound. And our fifth program under development.

​​

• NT-301 (Multi-Component Compound) addresses hypermobile Ehler’s Danlos Syndrome (hEDS). HEDS is a genetic connective tissue disorder primarily caused by mutations in the genes encoding collagen, particularly COL5A1 and COL5A2, which are involved in the production of type V collagen. The prevalence of this rare condition is estimated to affect anywhere from 1 in 5,000 to 1 in 20,000 individuals in the U.S.